BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, May 1, 2024
See today's BioWorld
Home
» Acacia delivers positive phase III readout for PONV candidate
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Acacia delivers positive phase III readout for PONV candidate
Oct. 7, 2014
By
Nuala Moran
No Comments
LONDON – In one of the things you seldom see in UK biotech, Acacia Pharma Ltd. has delivered positive phase III results for ADP421 in postoperative nausea and vomiting (PONV), and embarked on planning the route to commercialization in the U.S.
BioWorld